Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

Exclusion Criteria

• •Pregnant or nursing mother
• •Use of any antimicrobial agents (vaginal or systemic) for the treatment of any condition within 7 days
• •Presence of any intrauterine device
• •Allergy or hypersensitivity to valcyclovir or nucleoside analogues
• •Pregnancy (all women will have a urine pregnancy test prior to randomization and treatment)
• •nursing mother
• •Menopausal women
• •Use of any antimicrobial agents (vaginal or systemic) for the treatment of any condition within 7 days of study enrollment
• •Known immunocompromised state
• •Significant Medical disorder that precludes accurate evaluation of participants condition
• •Presence of any intrauterine device
• •History of significant hepatic or renal impairment
• •Sensitivity/allergy to valacyclovir or nucleoside analogues
• •history of acyclovir or valacyclovir resistant HSV infection
• •Participation in a study using an investigational product in the past 30 days